Vedolizumab
Description
Vedolizumab is a recombinant IgG1 kappa, humanized monoclonal antibody that selectively binds with Integrin alpha4 and beta7. It is an integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn’s disease in adults.
Product name | Vedolizumab Biosimilar |
Species | Homo sapiens |
Expression system | CHO-K1 |
Buffer | PBS, pH 7.4 |
Delivery condition | Dry ice (-80°C) |
Delivery Time | 1 week if in stock; 4 weeks if production needed |
Storage condition | Store at -80°C |
Brand | BioMetas |
Applications | ELISA, assay, in vivo |
Aliases/Synonyms | Entyvio, LDP-02, LDP02, MLN-02, MLN0002, MLN02 |
Reference | |
Note | For research use only. Not suitable for clinical or therapeutic use. |
Type | hIgG1, κ |
Clonality | Monoclonal Antibody |
Size | 1mg, 5mg, 10mg, 50mg, 100mg |
Brand | BioMetas |
Product type | Biosimilar |
Clonality | Monoclonal Antibody |
Expression system | CHO-K1 |
Applications | Elisa, assay, in vivo |
Contact Us for a Quote!
Data Gallery
Fig. 1.) 4-20% SDS-PAGE analysis
Recombinant protein was visualized by Coomassie Brilliant Blue R250 staining.
Fig. 2.) SEC-HPLC analysis
Column: Superdex 200 Increase 5/150 GL
Running buffer: 2xPBS, pH 7.4
